Eganelisib

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/​Refractory AML

Not Evaluated

What will happen during the trial?

The study consists of 2 parts:

  • Part 1: Dose Escalation (DE) in both monotherapy and in combination.
  • Part 2: Dose Optimization

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
125 patients (estimated)
Sponsors
Stelexis BioSciences
Tags
PI3K Inhibitor, High Risk, Randomization
Trial Type
Treatment
Last Update
SparkCures ID
2185
NCT Identifier
NCT06533761

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.